Side-by-side · Research reference

TeriparatidevsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED10/62 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Teriparatide

Vesugen

Primary target

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Not applicable — does not operate via hormone axis

Origin

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Teriparatide

Vesugen

Standard dose (osteoporosis)

20 mcg / day

FDA-approved regimen for severe osteoporosis.

—

Frequency

Once daily

Intermittent administration preserves anabolic effect.

Not specified in available literature

Maximum duration

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

—

Hypoparathyroidism dose

20 mcg / day

Used off-label for chronic hypoparathyroidism.

—

Evidence basis

RCT / FDA-approved

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Pelvic fragility fractures

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

—

Route

Subcutaneous (thigh or abdomen)

Subcutaneous or intramuscular

Timing

Morning or evening (flexible)

—

Storage

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

—

Pharmacogenetics

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

03Metabolic / Fat Loss Evidence

Parameter

Teriparatide

Vesugen

Fat loss application

None — teriparatide is a bone anabolic agent without direct lipolytic activity

—

04Side Effects & Safety

Parameter

Teriparatide

Vesugen

Hypercalcemia

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

—

Orthostatic hypotension

Dizziness, lightheadedness within hours of injection

—

Nausea

Common, usually mild and transient

—

Leg cramps / Arthralgia

Musculoskeletal pain reported in clinical trials

—

Hypercalciuria

Increased urinary calcium excretion; monitor for nephrolithiasis risk

—

Osteosarcoma (black box warning)

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

—

Injection site reaction

Erythema, bruising, pain (uncommon)

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Vesugen

—

Relative Contraindications

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Teriparatide

Vesugen

1. Device preparation

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Injection technique

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Monitoring

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

—

6. Calcium and vitamin D supplementation

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.

—

06Stack Synergy

Teriparatide

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)